Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2110801 | 0.84 | HTR6 (0.49) | HTR6LMNASMN1; SMN2CYP3A4HTR2A | |
| SCHEMBL5350219 | 0.80 | HTR6 (0.64) | HTR6LMNASMN1; SMN2PLK1CA12 | |
| SCHEMBL16698228 | 0.79 | HTR6 (0.43) | HTR6LMNASMN1; SMN2CYP3A4HTR2A | |
| SCHEMBL21805760 | 0.78 | AKR1C3 (0.49) | HTR6LMNASMN1; SMN2CYP3A4HTR2A | |
| SCHEMBL17097143 | 0.78 | HTR6 (0.56) | HTR6LMNASMN1; SMN2CYP3A4HTR2A | |
| SCHEMBL5643286 | 0.77 | HTR6 (0.42) | HTR6LMNASMN1; SMN2ALDH3A1BRD4 | |
| SCHEMBL19626251 | 0.76 | CA1 (0.43) | HTR6CYP3A4ALDH3A1CA1CA2 | |
| SCHEMBL12615516 | 0.76 | L3MBTL1 (0.42) | HTR6LMNASMN1; SMN2CYP3A4TNFSF11 | |
| SCHEMBL6039702 | 0.75 | HTR6 (0.53) | HTR6LMNASMN1; SMN2CYP3A4HTR2A | |
| SCHEMBL16990418 | 0.74 | HTR6 (0.54) | HTR6LMNASMN1; SMN2HTR2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758505-B2 | 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | ITEOS THERAPEUTICS (BE) | 2017-09-12 | — | — | US | disclosed |
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-09-15 | — | — | US | disclosed |
| EP-3066090-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | iTeos Therapeutics (BE) | 2016-09-14 | — | — | EP | disclosed |
| US-20150328228-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-11-19 | — | — | US | disclosed |
| US-9126984-B2 | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use | ITEOS THERAPEUTICS SA (BE) | 2015-09-08 | — | — | US | disclosed |
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-13 | — | — | US | disclosed |
| WO-2015067782-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133422-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS SA (BE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133422-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 101/4885LMNA 4584/4885SMN1; SMN2 1060/4885 |
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, TPH1 | HTR6 84/4885LMNA 4527/4885SMN1; SMN2 1576/4885 |
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 61/4885LMNA 4539/4885SMN1; SMN2 1374/4885 |
| US-20150328228-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 144/4885LMNA 4749/4885SMN1; SMN2 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.